HealthTech startup BlueSkeye AI has secured £3.4 million in funding to pursue its mission to improve people’s quality of life through face and voice analysis technology.
The round was led by XTX Ventures, which invested alongside Foresight Group, Praetura Ventures, the University of Nottingham and a consortium of high net-worth individuals.
BlueSkeye AI’s trademark blending of advanced research into expressive human behaviour with specialist expertise in computer vision, machine learning and AI has many important use cases.
In digital health & wellbeing, it is poised to transform the diagnosis of mental health conditions and improve care, whilst in the automotive industry it will significantly enhance safety and wellbeing for the drivers and passengers of vehicles.
The funding will further accelerate BlueSkeye AI’s expansion across both clinical and non-clinical health and wellbeing markets to transform patient pathways at scale.
This will support service providers to address the global worldwide need for early diagnosis of mental health issues such as depression and anxiety, and the development of new products to support accurate digital diagnosis in the health and wellbeing sector.
Spinal implant firm raises £10.8m after successful product release
As part of this investment, BlueSkeye AI will expand its activities with a physical presence in the North West of England.
Founded in 2019, BlueSkeye AI is a spinout from The University of Nottingham’s School of Computer Science. It was established by Professor Michel Valstar (CEO) and Dr Anthony Brown (CTO), and Chief Machine Learning and Software Engineer Dr Timur Almaev.
“The demand for alternative pathways to access mental healthcare is enormous, and continues to grow by the day,” said CEO Professor Valstar.
“We’re committed to disrupting traditional approaches to healthcare to help improve the quality of people’s lives, and we’re particularly focused on the perinatal mental health sector.
“With the support of XTX Ventures, Foresight Group and Praetura Ventures, we’ll strengthen the rollout of new clinical trials and product development, and champion the benefits of technology for reinforcing healthcare provision on a national, regional and global basis.”